Vascular occlusion disorder

Summary

Vascular occlusion disorder (MONDO:0020672) is a disease and 10 clinical trials. Top therapeutic interventions include minocycline, sodium chloride, and tirofiban. A subtype of vascular disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	vascular occlusion disorder
Mondo ID	MONDO:0020672
Is cancer (heuristic)	no

Also known as: vascular occlusion

Disease family

This is a subtype of vascular disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › vascular occlusion disorder

Related subtypes (59): arterial disorder, ischemic colitis, thrombotic disease, capillary disorder, angiodysplasia, hepatic vascular disorder, vascular hemostatic disease, vein disorder, ischemic disease, peripheral vascular disease, venous thromboembolism, ocular vascular disorder, cholesterol embolism, thoracic outlet syndrome, idiopathic spontaneous coronary artery dissection, cerebral arteriopathy with subcortical infarcts and leukoencephalopathy, angioosteohypertrophic syndrome, Bannayan-Riley-Ruvalcaba syndrome, arterial tortuosity syndrome, hereditary arterial and articular multiple calcification syndrome, pulmonary venoocclusive disease, multiple cutaneous and mucosal venous malformations, arterial dissection-lentiginosis syndrome, patent ductus arteriosus, multisystemic smooth muscle dysfunction syndrome, STING-associated vasculopathy with onset in infancy, capillary malformation, Ehlers-Danlos syndrome, vascular-like type, calciphylaxis, neonatal Marfan syndrome, Ehlers-Danlos syndrome, vascular type, lethal arteriopathy syndrome due to fibulin-4 deficiency, congenital portosystemic shunt, arterial calcification of infancy, vasculitis, Loeys-Dietz syndrome, skin vascular disease, lymphatic malformation, familial thoracic aortic aneurysm and aortic dissection, congenital anomaly of superior vena cava, congenital anomaly of the inferior vena cava, congenital anomaly of hepatic vein, congenital renal artery stenosis, internal carotid agenesis, coronary sinus stenosis, coronary sinus atresia, vascular insufficiency disorder, blood vessel neoplasm, vascular ectasia, vascular disorder of penis, fibrocartilaginous embolism, vascular malformation, lymphatic vessel neoplasm, neurovascular disorder, superior vena cava syndrome, coronary microvascular disorder, segmental arterial mediolysis, bleeding disorder, vascular-type, arterial tortuosity-bone fragility syndrome

Subtypes (2): retinal vascular occlusion, arterial occlusion

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE2/PHASE3	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07594314	PHASE2/PHASE3	RECRUITING	Minocycline After Successful Endovascular Thrombectomy Recanalization in Acute Anterior Circulation Large Vessel Occlusion (ATTRACTION-MINOA)
NCT00347711	PHASE3	WITHDRAWN	Bevacizumab and Retinal Vascular Occlusions
NCT06265051	PHASE2/PHASE3	COMPLETED	Tirofiban After Successful MT Recanalization in AIS
NCT02719665	Not specified	COMPLETED	THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease
NCT04277065	Not specified	UNKNOWN	Bulldog vs. Cotton Tourniquet in Laparoscopic Hepatectomy for Patients
NCT04451525	Not specified	COMPLETED	REal-World Analyses of Stroke - Thrombus Occlusion REtrieval
NCT04478422	Not specified	COMPLETED	Muscle Training With and Without Vascular Occlusion of Women With Patellofemoral Pain Syndrome: A Random Clinical Trial
NCT05311605	Not specified	UNKNOWN	REperfusion Therapy for Acute Ischemic STrOke Due to Large aRtEry Occlusion
NCT05342038	Not specified	WITHDRAWN	Study on the Efficacy and Safety of T-02 for the Treatment for Acute Ischemic Stroke
NCT05452109	Not specified	COMPLETED	Effect of Blood Flow Restriction on Football-Related Performance Parameters

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MINOCYCLINE	4	1
SODIUM CHLORIDE	4	1
TIROFIBAN	4	1
COTTON, PURIFIED	-1	1